| First Author | Blagih J | Year | 2020 |
| Journal | Cell Rep | Volume | 30 |
| Issue | 2 | Pages | 481-496.e6 |
| PubMed ID | 31940491 | Mgi Jnum | J:287255 |
| Mgi Id | MGI:6416067 | Doi | 10.1016/j.celrep.2019.12.028 |
| Citation | Blagih J, et al. (2020) Cancer-Specific Loss of p53 Leads to a Modulation of Myeloid and T Cell Responses. Cell Rep 30(2):481-496.e6 |
| abstractText | Loss of p53 function contributes to the development of many cancers. While cell-autonomous consequences of p53 mutation have been studied extensively, the role of p53 in regulating the anti-tumor immune response is still poorly understood. Here, we show that loss of p53 in cancer cells modulates the tumor-immune landscape to circumvent immune destruction. Deletion of p53 promotes the recruitment and instruction of suppressive myeloid CD11b(+) cells, in part through increased expression of CXCR3/CCR2-associated chemokines and macrophage colony-stimulating factor (M-CSF), and attenuates the CD4(+) T helper 1 (Th1) and CD8(+) T cell responses in vivo. p53-null tumors also show an accumulation of suppressive regulatory T (Treg) cells. Finally, we show that two key drivers of tumorigenesis, activation of KRAS and deletion of p53, cooperate to promote immune tolerance. |
